^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Published date:
12/01/2022
Excerpt:
Oncolytics Biotech® Inc....announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC)....at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, Oncolytics reported interim clinical data showing a 69% objective response rate (ORR) including a complete response (n=13) in a cohort of first-line advanced/metastatic PDAC patients treated with the combination of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel in the Company's phase 1/2 GOBLET study.
Secondary therapy:
gemcitabine + albumin-bound paclitaxel